Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Heart Journal

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AHJ.2003.11.003PMID 15077100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.

  2003cited by this paper
• Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients

  2002cited by this paper
• Acenocoumarol decreases tissue factor–dependent coagulation during systemic inflammation in humans

  2002cited by this paper
• Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects

  2002cited by this paper
• Clinical application of the PFA-100®

  2002cited by this paper
• Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

  2002cited by this paper
• Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion

  2002cited by this paper
• Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro model

  2002cited by this paper
• Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.

  2002cited by this paper
• Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

  2001cited by this paper
• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

  2001cited by this paper
• Differential Effects of Citrate Versus PPACK Anticoagulation on Measured Platelet Inhibition by Abciximab, Eptifibatide and Tirofiban

  2001cited by this paper
• Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.

  2001cited by this paper
• αIIbβ3 and Its Antagonism at the New Millennium

  2001cited by this paper
• AlphaIIbbeta3 and its antagonism at the new millennium.

  2001cited by this paper
• Circulating Monocyte-Platelet Aggregates Are a More Sensitive Marker of In Vivo Platelet Activation Than Platelet Surface P-Selectin: Studies in Baboons, Human Coronary Intervention, and Human Acute Myocardial Infarction

  2001cited by this paper
• Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?

  2001cited by this paper
• Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.

  2001cited by this paper
• Adhesive Interactions of Leukocytes, Platelets, and the Vessel Wall during Hemostasis and Inflammation

  2001cited by this paper
• ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations.

  2000cited by this paper
• A critical appraisal of platelet glycoprotein IIb/IIIa inhibition.

  2000cited by this paper
• Paroxetine decreases platelet serotonin storage and platelet function in human beings

  2000cited by this paper
• Monitoring of Aspirin (ASA) Pharmacodynamics with the Platelet Function Analyzer PFA-100®

  2000cited by this paper
• Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.

  2000cited by this paper
• Systemic inflammation increases shear stress‐induced platelet plug formation measured by the PFA‐100

  2000cited by this paper
• The TETAMI Trial: The Safety and Efficacy of Subcutaneous Enoxaparin versus Intravenous Unfractionated Heparin and of Tirofiban versus Placebo in the Treatment of Acute Myocardial Infarction for Patients Not Thrombolyzed: Methods and Design

  2000cited by this paper
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.

  2000cited by this paper
• Use of the PFA-100™ Apparatus to Assess Platelet Function in Patients Undergoing PTCA during and after Infusion of cE3 Fab in the Presence of other Antiplatelet Agents

  2000cited by this paper
• Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100

  2000cited by this paper
• Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors.

  1999cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.

  1999cited by this paper
• Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.

  1999cited by this paper
• Meloxicam, 15 mg/day, spares platelet function in healthy volunteers

  1999cited by this paper
• Rapid platelet-function assay: an automated and quantitative cartridge-based method.

  1999cited by this paper
• Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen.

  1999cited by this paper
• Effects of Endotoxemia on Thrombopoiesis in Men

  1999cited by this paper
• Enhanced shear-induced platelet aggregation in acute myocardial infarction.

  1999cited by this paper
• Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.

  1999cited by this paper
• Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin.

  1999cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998cited by this paper
• Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.

  1998cited by this paper
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

  1998cited by this paper
• Platelet aggregation in flow: differential roles for adhesive receptors and ligands.

  1998cited by this paper
• Clinical pharmacology of eptifibatide.

  1997cited by this paper
• Effects of Integrelin on platelet function in flow models of arterial thrombosis.

  1997cited by this paper
• von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?

  1997cited by this paper
• von Willebrand factor.

  1997cited by this paper
• Increased neutrophil-platelet adhesion in patients with unstable angina.

  1996cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.

  1995cited by this paper
• Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

  1995cited by this paper
• Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

  1995cited by this paper
• Increased soluble form of P-selectin in patients with unstable angina.

  1995cited by this paper
• Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

  1995cited by this paper
• von Willebrand factor release induced by endotoxin.

  1989cited by this paper
• Sample size calculations for clinical pharmacology studies

  1986cited by this paper

• Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic imaging on a chip.

  2022cites this paper
• Letter in response to: circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality

  2021cites this paper
• COVID-19 and Delayed Cerebral Ischemia—More in Common Than First Meets the Eye

  2021cites this paper
• The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer

  2020cites this paper
• The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin

  2020cites this paper
• von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo

  2020cites this paper
• Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence

  2018cites this paper
• The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice.

  2016cites this paper
• Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial.

  2016cites this paper
• Test Principle Advantages Limitations Sensitivity to antiplatelet drugs Bleeding time In vivo cessation of blood flow Widely

  2015cites this paper
• Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy.

  2014cites this paper
• Analysis of Aptamer Concentrations in Cynomolgus Macaque Plasma and in the Serum Stability Study

  2012cites this paper
• ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion

  2012cites this paper
• Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.

  2012cites this paper
• Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy

  2010cites this paper
• Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia

  2010cites this paper
• Platelet function tests and resistance to antiplatelet therapy.

  2010cites this paper
• The aptamer ARC1779 blocks von Willebrand factor–dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

  2010cites this paper
• Racial differences in endotoxin‐induced tissue factor‐triggered coagulation

  2009cites this paper
• Can We Predict Bleeding?

  2008cites this paper
• Altered platelet plug formation in hyperthyroidism and hypothyroidism.

  2007cites this paper
• EFFECTS OF THE PAN-SELECTIN ANTAGONIST BIMOSIAMOSE (TBC1269) IN EXPERIMENTAL HUMAN ENDOTOXEMIA

  2007cites this paper
• Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function

  2006cites this paper
• Duration of effects of aspirin on platelet function in healthy volunteers: an analysis using the PFA-100.

  2006cites this paper
• Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS

  2006cites this paper
• Coagulation interventions in experimental human endotoxemia.

  2006cites this paper
• Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation

  2005cites this paper
• Platelets and new antiplatelet drugs

  2005cites this paper
• New drugs and directions

  2005cites this paper
• The platelet-function analyzer (PFA-100 ® ) for evaluating primary hemostasis

  2005cites this paper
• Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide

  2005cites this paper
• Platelet Function Predicts Myocardial Damage in Patients With Acute Myocardial Infarction

  2004cites this paper